GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apyx Medical Corp (NAS:APYX) » Definitions » Debt-to-EBITDA

Apyx Medical (Apyx Medical) Debt-to-EBITDA : -1.16 (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Apyx Medical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Apyx Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.37 Mil. Apyx Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $38.13 Mil. Apyx Medical's annualized EBITDA for the quarter that ended in Dec. 2023 was $-33.08 Mil. Apyx Medical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Apyx Medical's Debt-to-EBITDA or its related term are showing as below:

APYX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.13   Med: -0.14   Max: -0.01
Current: -2.13

During the past 13 years, the highest Debt-to-EBITDA Ratio of Apyx Medical was -0.01. The lowest was -2.13. And the median was -0.14.

APYX's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs APYX: -2.13

Apyx Medical Debt-to-EBITDA Historical Data

The historical data trend for Apyx Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apyx Medical Debt-to-EBITDA Chart

Apyx Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.04 -0.02 -0.04 -2.13

Apyx Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.44 -13.91 -0.85 -1.16

Competitive Comparison of Apyx Medical's Debt-to-EBITDA

For the Medical Devices subindustry, Apyx Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apyx Medical's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Apyx Medical's Debt-to-EBITDA falls into.



Apyx Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Apyx Medical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.367 + 38.134) / -18.112
=-2.13

Apyx Medical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.367 + 38.134) / -33.076
=-1.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Apyx Medical  (NAS:APYX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Apyx Medical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Apyx Medical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Apyx Medical (Apyx Medical) Business Description

Traded in Other Exchanges
Address
5115 Ulmerton Road, Clearwater, FL, USA, 33760
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Executives
Todd Hornsby officer: Executive Vice President 14321 HAWTHORNE DR., CARMEL IN 46033
Goodwin Charles D. Ii director, officer: Chief Executive Officer 5115 ULMERTON ROAD, CLEARWATER FL 33760
Wendy Lauren Levine director 75 KENMARE STREET, APT. 2D, NEW YORK NY 10012
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Tara Semb officer: Chief Financial Officer 5516 RIVERSIDE HEIGHTS WAY, RICHMOND VA 23225
Craig A. Swandal director 5115 ULMERTON ROAD, CLEARWATER FL 33760
Michael Geraghty director 1342 CHERRY HILL ROAD, MENDOTA HEIGHTS MN 55118
Lawrence Waldman director 5115 ULMERTON RD., CLEARWATER FL 33770
John C. Andres director 86 CAPRI LANE, CHATHAM MA 02633
Jay D. Ewers officer: Chief Financial Officer 4 MANHATTANVILLE ROAD, SUITE 106, PURCHASE NY 10577
J Robert Saron director, officer: President
Robert Gershon director, officer: Chief Executive Officer 5115 ULMERTON ROAD, CLEARWATER FL 33760
Mccarthy John J. Iii officer: Chief CommercializationOfficer 23 RINALDO ROAD, NORTHPORT NY 11768
Scott Richard Davidson director C/O GREAT POINT PARTNERS, LLC, 165 MASON STREET, GREENWICH CT 06830
Moshe Citronowicz officer: Vice President of Operations

Apyx Medical (Apyx Medical) Headlines

From GuruFocus

Chuck Royce Adds Apyx Medical Corp to Portfolio

By GuruFocus Research 01-24-2024